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Mitochondria (MT), themajor site of cellular energy production, are under dual genetic control by 37mitochondrial DNA (mtDNA) genes
and numerous nuclear genes (MT-nDNA). In the CHARGEmtDNAþ Consortium, we studied genetic associations of mtDNA and MT-
nDNAassociationswith bodymass index (BMI), waist-hip-ratio (WHR), glucose, insulin,HOMA-B,HOMA-IR, andHbA1c. This 45-cohort
collaboration comprised 70,775 (insulin) to 170,202 (BMI) pan-ancestry individuals. Validation and imputation of mtDNA variants was
followed by single-variant and gene-based association testing. We report two significant common variants, one in MT-ATP6 associated
(p% 5E04) with WHR and one in the D-loop with glucose. Five rare variants inMT-ATP6,MT-ND5, andMT-ND6 associated with BMI,
WHR, or insulin. Gene-basedmeta-analysis identifiedMT-ND3 associated with BMI (p% 1E03). We considered 2,282MT-nDNA candi-
date gene associations compiled from online summary results for our traits (20 unique studies with 31 dataset consortia’s genome-wide
associations [GWASs]). Of these, 109 genes associated (p% 1E06)with at least 1 of our 7 traits.We assessed regulatory features of variants
in the 109 genes, cis- and trans-gene expression regulation, and performed enrichment and protein-protein interactions analyses. Of the
identifiedmtDNAandMT-nDNAgenes, 79 associatedwith adiposemeasures, 49with glucose/insulin, 13with risk for type 2diabetes, and
18 with cardiovascular disease, indicating for pleiotropic effects with health implications. Additionally, 21 genes related to cholesterol,
suggesting additional important roles for the genes identified.Our results suggest thatmtDNAandMT-nDNAgenes and variants reported
make important contributions to glucose and insulin metabolism, adipocyte regulation, diabetes, and cardiovascular disease.Introduction
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The dual genomic origin (mtDNA and MT-nDNA) of MT
components and the fact that mtDNA has a much higher
mutation rate compared to the nuclear genome9,10 fuels
our hypothesis that MT variants influence individual
predisposition to complex diseases.11,12 Because of hetero-
plasmy, i.e., the coexistence of mutated and wild-type
mtDNA in the same cell, mutations in mtDNA may not
result in disease until the copy number of mtDNA carrying
the mutation relative to the wild-type mtDNA in the
relevant tissue(s) exceeds a threshold.12 The mtDNA copy
number may serve as an indicator of MT function13 and
was recently shown to be associated with overall mortal-
ity14,15 and various metabolic-related diseases, including
cardiovascular disease (CVD).16–18 Studies have also shown
that mitochondria have an important influence on multi-
ple cardiovascular disease risk factors. For example, obesity
impairs MT biogenesis.19–21 MT dysfunction has been also
implicated in the development of insulin resistance.22–24
Thus, our study prioritized obesity and insulin resistance
pathways to CVD.
In our study we analyzed the dual genomic influence of
MT function on seven important metabolic traits (body
mass index [BMI], waist-hip ratio [WHR], fasting glucose,
fasting insulin, HOMA-B, HOMA-IR, and HbA1c) as major
risk factors of cardiovascular disease (CVD) in participants
of the CHARGEmtDNAþ 45 participating cohorts. The
mtDNA associations were evaluated at both the single
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114 The American Journal of Human Genetics 104, 112–138, Januaryrare alleles (minor allele frequency [MAF] < 1%). The
MT-nDNA candidates were studied for function, gene
expression regulation, enrichment of pathways, and
protein interactions. The overall goal was to illuminate
MT-functioning and MT-disease causative variants.Subjects and METHODS
CHARGE Cohorts
There were 45 participating cohorts with a total of 196,967 indi-
viduals (166,423 individuals were of the European [EA], 15,745
of African [AA], 1,567 of Asian [ASA], 11,307 of Hispanic/Latinos
[HA], and 1,925 of Brazilian ancestry) who had at least one of
the seven traits. CHARGE cohort summary descriptions are avail-
able online (see Supplemental Study Descriptions). The number
of samples available from all cohorts differed by phenotype (Table
S1). The resulting samples were smaller within each cohort when
association tests were performed (by sub-setting individuals with
genotyping available) to a total of 170,202 for BMI, 155,396 for
WHR, 79,906K for fasting glucose, 70,778 for fasting insulin,
69,845 for HOMA-B, 69,926 HOMA-IR, and 101,218 for HbA1c.
We use the acronym PA to refer to pan-ancestry. The procedures
followed were in accordance with the ethical standards of the
responsible committee on human experimentation (institutional
and national) and that proper informed consent was obtained.
Trait Harmonization
A total of seven traits were studied: BMI (kg/m2), WHR (waist-hip
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Figure 1. Graphical Presentation of Sin-
gle mtDNA- and Gene-Based Association
Meta-Analysis Results
Significant associations (trait, MT position,
and p value) at liberal threshold (p %
1E03) are annotated with red arrows
and gray text for single SNV associations
and with green arrow for gene-based asso-
ciation, and text in red color represents
SNVs that passed the threshold p %
5E04. The asterisk (*) marks missense or
synonymous variants; a dagger (y) marks
a SKAT gene-based significant association.
The mtDNA is shown as one single mole-
cule, by merging all genes from heavy
and light MT strands. For visibility, gene
colors rotate clockwise from first in blue
in the D-loop to up to six coloring groups
finishing in red at MT-TL1, and then recy-
cling again from the first blue color at
MT-ND1. The full information is summa-
rized in Tables 1, 2, 3, and S2.a-S2.b. In
blue text are shown bps-positions of 13
MT-coding genes (MT-ND1, MT-ND2, MT-
CO1, MT-CO2, MT-ATP8, MT-ATP6, MT-
CO3, MT-ND3, MT-ND4L, MT-ND4, MT-
ND5, MT-ND6, MT-CYB), 2 MT-ribosomal
RNAs (MT-RNR1 [12S RNA] and MT-RNR2
[16S RNA]), and 22 transport RNAs (MT-
TF, TV, TL1, T1, TQ, TM, TW, TA, TN, TC,
TY, TS1, TD, TK, TG, TR, TH, TS2, TL2,
TE, TT, TP).HOMA-B, HOMA-IR, and glycated hemoglobin (HbA1c, %) indica-
tive of chronically elevated glucose levels. The homeostasis model
assessmentwas based onplasma levels of fasting glucose and fasting
insulin. HOMA-B is an indicator of beta-cell function calculated as
HOMA-B ¼ (360 3 fasting insulin) / (fasting glucose  60).
HOMA-IR is an indicator of insulin resistance calculated as HOMA-
IR ¼ (fasting glucose 3 fasting insulin) / 405. Glucose and insulin
measures were required to have been measured with a minimum
fasting time of 8 hr; otherwise, the measure was set to missing.
Each studywas responsible for ensuring that each trait wasnormally
distributed. Natural-log transformation was implemented for insu-
lin, power transformation was performed when no other solutions
were available, and inverse normal transformation was used as a
last resort for BMI25 (details in the Supplemental Material and
Methods, section 1). The association test analysis was restricted to
non-diabetic participants when studying glycemic traits, by setting
values of glucose, insulin, andHbA1c tomissing for T2D individuals
withHbA1c> 6.5 or with fasting glucose> 126mg/dL or using T2D
medications. Theparticipating cohortswere required tohave at least
one of the seven studied metabolic traits.
Preparation of Traits for Analyses
All cohorts used the same units for all traits for the raw measures.
We observed differences in the raw measures of traits (Table S1).
Thus, to harmonize results, all participating cohorts normalized
trait distributions and produced standardized residuals, which
are unit-less for each trait. Statistical regression via R / SAS pro-
gramming languages was used to produce residuals fitting the
following model:
trait ¼ ageþ age2 þ sexþ PCs
þ other study specific covariates ðe:g:; study center; etcÞThe AmericAge2 was used to remove any age-quadratic trend from the
response variable, and principal components (PCs) represent one
or more genotype principal components, to minimize population
substructure. The standardized residuals from this regression were
the final response variables for each trait, used in the association
tests with imputed dosages of mtDNA.
mtDNA Variant Harmonization
All mtDNA variants from each array (Table S14) were annotated to
the nucleotide position according to the rCRS of the humanmito-
chondrial DNA prior to analyses (see Web Resources). The probes
used for each microarray were obtained from the manufacturer
or dbSNP and aligned to the rCRS using Geneious 8.1.26 All probes
were also submitted through the standard nucleotide basic local
alignment search tool (BLAST) to ensure the probes bound with
high specificity (R90% identity) to the mitochondrial genome.
In order to limit any potential binding to nuclear DNA segments,
probes that bound to nuclear chromosomes withR80%matching
were excluded from all analyses. The full lists of the validated
mtDNA variants are available in the Supplemental Material and
Methods, section 2 and Tables S15–S28.
mtDNA Imputation
The preparation of mtDNA data for imputation was done with
PLINK.27,28 When preparing data for imputation, a few heterozy-
gotes that may have existed in the mtDNA genotypes were set to
missing via PLINK. The prephasing of mtDNA scaffold haplotypes
at the cohort level was done with SHAPEIT2 for the full mtDNA
(seeWeb Resources).29 SHAPEIT2 helped to have themtDNA geno-
types of a cohort in the right format to be used in the imputation
pipeline with IMPUTE2. SHAPEIT2 was also used for QC checks,
such as evaluating missingness in markers. In order to combinean Journal of Human Genetics 104, 112–138, January 3, 2019 115
analyses across different genotyping platforms, we performed
imputation based on MT-1000G (see Supplemental Material and
Methods, section 3). Imputations of mtDNA variants were imple-
mented in IMPUTE2 at the cohort level in a window that included
the full MT-chromosome (seeWeb Resources).30 Recoding of geno-
type probabilities into dosages was implemented via FCGENE (see
Web Resources). Our reference MT-chromosome panel consisted
of the 1000G data (PHASE 3, v.5) (see Web Resources). These
data were based on sequence freeze and alignments, using only
Illumina platform sequences and only sequences with read
lengths of 70 bps or greater. There were 3,617 mtDNA markers
in 1000G. The 1000G included 2,504 individuals representing
26 sampled populations (the ‘‘Cosmopolitan’’ reference panel).31
After imputation, cohorts had differing number of SNVs, up to
3,832 SNVs for BMI, 3,829 for WHR, 3,809 for glucose, 3,801 for
insulin, 3,801 for HOMA-B, 3,801 for HOMA-IR, and up to 3,744
for HbA1c. Although the imputation quality was good for most
of cohorts (see imputation accuracy in Table S14), a great number
of the SNVs were filtered for INFO (imputation quality) < 0.30,
monomorphic or very rare (MAF < 0.0001) at the cohort level
before association tests. Other QC were genotype call per cell
had to be p R 0.90, a marker was dropped if its missing rate was
>0.05 and MAC had to be R5, (which if it was autosomal could
have corresponded to MAC R10). The MAC was calculated for
haplotypes as MAF*N. (See Supplemental Material and Methods,
section 3 for a more detailed methodology.) After mtDNA imputa-
tion, before performing statistical associations, we set any hetero-
plasmic mutations to missing at the cohort level data. Details of
QC via R Package: EasyQC (V10.0)32 (see Web Resources) and
our internal programs and of the imputation steps can be found
in the Supplemental Material and Methods, section 3. All filters
implemented at the cohort level created non-uniform contribu-
tions of all cohorts in the meta-analysis. Many of the mtDNA var-
iants were rare and per trait meta-analyses QQ-plots often showed
an underestimation compared to expected association results (Fig-
ures S1–S7). The rarity of alleles was accompanied with lower
quality of imputation and accordingly many of them were
removed before anymeta-analysis. Most studies had good imputa-
tion quality, given the rarity of mtDNA variants.
Variants MT-14272 and MT-14584 are opposite C/T versus T/C,
but in full LD, while they are rare. The typical assumption is that
rare variants are not in LD, but that does not have to hold for
mtDNA. This is one more observation that the rare association
findings in this study represent potential associations, until repli-
cated from other future studies.mtDNA Association Statistical Analyses
An additive genetic model was applied in association analyses
using both self-developed regression models (the linear or linear
mixed models written in R programming) and the SKAT (the prep-
Scores() function in seqMeta R package: seqMeta package:
Meta-Analysis of Region-Based Tests of Rare DNA Variants ap-
proaches33 (see Web Resources). Familial and maternal correlation
structures34 were accounted for in the analysis of family data.
Details of statistical association models 1–4 are described in the
Supplemental Material and Methods, section 4.mtDNA Meta-Analyses
Single-variant fixed-effects meta-analyses were conducted with
METAL,35 and gene-based associations were performed in seqMeta
(details in the Supplemental Material and Methods, sections 5–7)116 The American Journal of Human Genetics 104, 112–138, January(Tables 1, 2, 3, S2.a, S2.b, and S13). The average allele
frequency from Metal is an average of allele frequencies for
a particular marker as contributed from each study and weighted
by each study’s sample size as follows: Freq1WeightAve ¼
Ps
k¼1wkfk=
Ps
k¼1wk, where k represents the indexing of contrib-
uting studies, wk is the sample size (number of individuals) per
study, and fk is the coded allele frequency for a particular marker
from a particular study. Our working group conducted an internal
permutation test36 using ARIC study mtDNA data and determined
that 49 independent mitochondrial variants represented an esti-
mate of the number of independent genetic effects for mtDNA.
Thus, 49 was used as a denominator for producing the Bonferroni
corrected p significance threshold % 0.05/49 % 1E03, a
threshold for common variants (MAF R 1%), but possibly liberal
for rare variants (MAF< 1%) (Table 1). Furthermore, we considered
p % 0.05/(49 3 7 traits) % 1.5E04 as a conservative threshold
when accounting for seven traits tested. We settled for a Bonfer-
roni-threshold p % 0.05/(49 3 2 domains) % 5E04, because
the traits within a domain adipose/obesity (BMI and WHR) and
glucose metabolism (glucose, insulin, HOMA-B, HOMA-IR, and
HbA1c) are correlated and represent two domains. Because
mtDNA is a small genome, the distributions of mtDNA QQ-plots
with the existing samples do not always behave similarly to those
observed for larger nuclear GWASs.While mtDNA variantsMAFR
1% formed relatively good QQ-plot distributions, the rare variants
(MAF < 1%) were sometimes distributed with some deviation in
the start (bottom-left) of the QQ-plot, as a result of meta-results
in very rare alleles. Thus, the quality control of mtDNA QQ-plots
were implemented by filtering at different rare MAF levels. We
concluded that with the existing mtDNA meta-analysis results,
QQ-plots with MAF > 0.8% were acceptable. Thus, out of 23
SNVs nominally (p % 1E03) associated with 6 metabolic traits
(Figure 1), by adding the filter of MACR 5 for each cohort, then
7 variants passed p% 5E04 Bonferroni threshold.
For the gene-based analysis, we used Burden tests which
combine the contributions of rare genetic variants within a gene
region. Such tests assume similar directionality and effect sizes
for each variant.33 In contrast, the sequence kernel association
test (SKAT) for unrelated or family-based studies is an efficient
regression-based approach for rare genetic variant anal-
ysis.33,37,38 The meta-analyses were performed using seqMeta
(seeWeb Resources). The gene-based Bonferroni p value was calcu-
lated as p% 0.05/ (37 mtDNA genes)% 1E03.Identification of MT-nDNA Candidate Genes
We established a list of 2,282 MT-nDNA candidate genes from
three sources: (1) Mito Carta 2.0,6,39 (2) Literature Lab (Acumenta
Biotech), and (3) MitoMiner (4.0)7 (see also Supplemental Material
and Methods, section 7). We used the two separate sets of human
genes and mouse ortholog genes from MitoCarta. We used Litera-
ture Lab to perform a literature search and identified 36 terms
based on MeSH mitochondria. From each of the 36 terms (Table
S29), we selected only the upper quartile list of genes from a Log
Probability Function - scoring distribution. Each term was tested
for association in overlapping with genes in pathway analysis
(Figure S15).We conditioned this list with only genes from human
nomenclature and accepted only genes that had more than 15 ab-
stracts cited per selected gene (see Supplemental Material and
Methods section 7).
Using MitoMiner we identified additional MT-nDNA candidate
genes. They were filtered with a MT-MitoMiner index R 0.70,3, 2019
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The Americand by selecting the terms ‘‘Knownmitochondrial’’ and ‘‘Predicted
mitochondrial.’’ In MitoMiner, we kept only genes that were pre-
sent in human nomenclature. MitoMiner included also the mito-
chondrial originated genes, which were later removed to keep our
MT-nDNA list only of nuclear origin. Finally, three additional
genes were added from a publication on MT-defects associated
with b-cell dysfunction in a T2D mouse.40MT-nDNA Candidate Genes Analysis
As a result of the above work, a list of 2,282 MT-nDNA candidate
gene labels (Table S30) were used to identify any significant results
from 20 GWAS papers full summary results for seven metabolic
traits, representing 31 datasets (Tables 4, S4, and S6). For the adi-
pose traits, the GWAS publication full summary results used
were for BMI41–50 and forWHR,43,44,47–52 and the summary results
data were retrieved from the GIANT Consortium repositories (see
Web Resources). For glucose metabolism we used the summary re-
sults of glucose,53–56 insulin,54–59 HOMA-B,54 and HOMA-IR.54
These summary results data were retrieved from MAGIC Con-
sortium archives (see Web Resources). For HbA1c we used two re-
sources.60,61 The published GWASs have large sample sizes, with
a BMI study having a maximum of 339K individuals, WHR having
320K, glucose and insulin having 52K and 45K, respectively,
HOMA-B and -IR having 46K, and HbA1c having 160K. Conse-
quently, we obtained results for 109 MT-nDNA candidate
genes, accompanied by 588 sentinel significant SNVs (one best
per gene and trait combination, out of seven traits, Tables 4, S6,
and S9).
To identify the 588 SNVs, a pre-specified selection process was
followed. First, we downloaded the latest dbSNP of NCBI reference
data (batch 150), and we assigned each SNV to a gene (pseudo-
genes excluded). The intergenic variants were assigned to the
closest gene, up to half the distance between two genes. Then,
we merged the 31 full-GWAS sets to the annotated dbSNP, thus
each GWAS-SNP was assigned to a gene. Each summary result
was merged with MT-nDNA gene labels (Table S30). The corre-
sponding significant SNVs results, ones with the smallest p value,
per gene and per trait, were accepted in the final list (p < 0.05/
(2,282 3 7) ¼ 3.13E06). After this selection, we also performed
an analysis based on 1000 Genomes to identify the number of in-
dependent SNVs within a gene.36,62 The analysis produced amean
of independent SNVs per gene of 59, median of 38, and with a
maximum of two outliers 542 (WWOX [MIM: 605131]) and 499
(FHIT [MIM: 601153]). If it was a gene-based test, then a conserva-
tive threshold p % 0.05/(542 3 7 traits) % 1.3E05 could have
been used, which is larger than the threshold we used, p %
1E06). Furthermore, to compare whether our MT-nDNA genes
pass the genome-wide threshold of p % 5E08, generally used
in GWAS publications, we merged our gene data with all possible
reported SNVs from the GWAS-Catalog (accessed 01.27.2018,
Table S12 and presented findings in the Results and Discussion
paragraphs).Annotation, Enrichment Analysis, and Gene Expression
and Regulation
The mtDNA as well as MT-nDNA significant variants were anno-
tated to NCBI dbSNP build 150 (HG38); genes and their protein
biological functions were annotated to NCBI Entrez Gene,
GeneCards and UniProtKB; enrichment analyses were performed
with MetaCore and Literature Lab; pathways with KEGG and
Reactome; gene expression and regulation were assessed usingan Journal of Human Genetics 104, 112–138, January 3, 2019 117
Table 2. Results of mtDNA Gene-Based Meta-analysis SKAT T1 and T5 Test (p % 0.01)
Trait Ancestry T Gene p Qmeta cMAF nSNVs
HOMA-B PA 0.01 MT-TF 5.0E03 4604374 0.022 5
HOMA-B PA 0.05 MT-TV 8.0E03 3341460 0.078 6
HbA1c EA 0.05 MT-TG 9.0E03 13674145 0.064 13
BMI PA 0.05 MT-TQ 1.0E02 21201188 0.075 12
HOMA-B PA 0.05 MT-RNR1 1.0E02 69787232 1.323 119
Abbreviations and definitions: Trait, the trait used for a specific test; PA, Pan ancestry; EA, European ancestry; T, MAF-value threshold for selecting SNVs to be
included in the gene-based association test; Gene, gene name from mtDNA; p, p value from the SKAT test; Qmeta, the SKAT Q statistics; Q ¼Pjw2j U2j , where
w is a weight for SNVj and Uj is associated score statistics; cMAF, cumulative minor allele frequency; nSNVs, the number of SNVs used in the gene-based meta-
analysis.HaploReg, RegulomeDB, GTEx, and Human Protein Atlas; and
protein interactions were assessed using STRING and NCBI sum-
mary of interactions from other databases (see Web Resources),
with references to databases BIND, BioGRID, EcoCyc, HIV-1-
human protein interaction data, and HPRD. Specifically, for
GTEx gene expression eQTL analysis, the eSNVs were considered
significant when the eSNV had a GTEx p < 1E07 and was in
high LD (r2R 0.80) with the best eSNVof the target gene. Depend-
ing on r2 R 0.80 to 1, we called them similar to ‘‘lead’’ or ‘‘lead’’
eSNVs. Otherwise, if the LD r2 was < 0.02 to the target gene’s
best eSNV, we called them ‘‘secondary’’ eSNVs (Table S8). Details
of the resources and the corresponding references are provided
in the Supplemental Material and Methods, sections 8 and 9. We
have cited throughout the manuscript the corresponding gene
MIM number from the Online Mendelian Inheritance in Man
(see Web Resources).Results
We evaluated the associations of mtDNA variants with
seven key metabolic traits in meta-analyses of 45 cohorts
(with up to N170,202). For details on the harmonization
of the phenotypes and genotypes, see Material and
Methods and Supplemental Material and Methods, sec-
tions 1–6. The Supplemental Study Descriptions and Table
S1 with BMI mean and standard deviation values give a
depiction of each contributing cohort in this study.
mtDNA Single-Variants Associations
Seven SNVs, two variants with average weighted
MAF > 1% (Tables 1 and S2.a and Figures S1–S7) and five
with MAF < 1% (Tables 1 and S2.b) displayed statistically
significant evidence of association with six metabolic traits
(Bonferroni threshold p % 5E04, see in Material and
Methods: mtDNA Meta-Analyses). MT-8706 in MT-ATP6
(MIM: 516060) (see Web Resources), associated with
WHR (with sample weighted average of cohorts’ MAF ¼
3.24%, p ¼ 4.1E04) and MT-16320 (rs62581338) of the
D-loop (with sample weighted average of cohorts’ MAF ¼
1.58%, p ¼ 7.6E05) associated with fasting glucose.
The five rare variants were MT-8896 (rs202120082,
missense) in MT-ATP6 associated with WHR, MT-14124
in MT-ND5 (MIM: 516005) associated with fasting plasma
insulin, MT-14272 in MT-ND6 (rs2853814 [MIM: 516006],118 The American Journal of Human Genetics 104, 112–138, Januarymissense) associated with BMI, MT-14353 in MT-ND6
associated with WHR, and MT-14584 in ND6 associated
with BMI.
The evidence of association by cohort is reported in Ta-
bles S2.a, S2.b, and S3. Typically, the cohort with a large
sample size displayed the strongest evidence of association.
For example, the HCHS/SOL study contributed dispropor-
tionately to several mtDNA-trait associations (see in the
Supplemental Study Descriptions, CHARGEmtDNAþ
StudyDescription). Even further, for theMT-ATP6 (position
8706) association with WHR, the strongest association in
HCHS/SOL was in those of Central/South American back-
ground (so more Native American ancestry as compared
to African American ancestry, Tables S2.a and S3).
mtDNA Rare Variants Gene-Based Associations
The mitochondrial rare variants for gene-based analysis
were mapped to the start and end positions of each gene
from the NCBI Reference Sequence GenBank: NC_
012920.1 (see Web Resources). The rare variant gene-based
meta-analysis using SKAT did not yield any significant
associations. In contrast, the Burden test yielded a signifi-
cant association between rare variants in MT-ND3 and
BMI (p ¼ 1E03, T < 0.05 including 82 SNVs). A forest
plot representing the 82 SNVs and the overall MT-ND3-
overall meta is shown in Figure S17. Several gene-
HOMA-B, HbA1c, and BMI associations were suggestively
significant employing both the SKAT and Burden ap-
proaches (MT-RNAs MT-TF [MIM: 590070], MT-TV [MIM:
590105], MT-TG [MIM: 590035], MT-TQ [MIM: 590030],
and MT-RNR1 [MIM: 561000]; p % 1E02; Tables 2 and
3). A total of 131 (T5-test) and 123 (T1-test) low-frequency
and/or rare variants contributed to T5-test and T1-test,
respectively. We used two gene-based approaches, burden
test and sequence kernel association test (SKAT), to eval-
uate the association between a gene and a phenotype.
Burden tests access the cumulative effects of multiple
variants by assuming that all variants have the same direc-
tionality in a genetic region. SKAT tests use a score-based
variance component framework without assuming that
all variants have the same directionality. Although the
two methods are different, they all evaluate aggregate
effects of multiple low-frequency and/or rare variants3, 2019
Table 3. Results of mtDNA Gene-Based Burden T1 and T5 Meta-Analysis Test (p % 0.01)
Trait Ancestry T Gene p Beta SE cMAFUsed nSNVs
BMI PA 0.05 MT-ND3 1.0E03 0.007 0.002 0.290 82
BMI PA 0.05 MT-TQ 2.0E03 0.020 0.006 0.075 12
BMI PA 0.05 MT-CO2 5.0E03 0.003 0.001 0.491 155
HOMAB PA 0.01 MT-TF 5.0E03 0.038 0.014 0.022 5
HOMAB PA 0.01 MT-TV 6.0E03 0.088 0.032 0.009 2
HOMAB PA 0.05 MT-RNR1 7.0E03 0.002 0.001 1.323 119
HOMAIR EA 0.05 MT-TG 7.0E03 0.027 0.010 0.061 13
BMI EA 0.05 MT-ND3 7.0E03 0.006 0.002 0.194 81
HOMAB PA 0.05 MT-TV 8.0E03 0.031 0.011 0.078 6
BMI EA 0.05 MT-TQ 8.0E03 0.018 0.007 0.064 12
HOMAB EA 0.05 MT-RNR1 9.0E03 0.002 0.001 1.287 120
HOMAB EA 0.05 MT-TF 9.0E03 0.018 0.007 0.127 10
HOMAB EA 0.05 MT-TV 9.0E03 0.030 0.011 0.079 6
HOMAB EA 0.01 MT-RNR1 1.0E02 0.003 0.001 0.292 61
Abbreviations and definitions: Trait, the trait used for a specific test; PA, Pan ancestry; EA, European ancestry; T, MAF-value threshold for selecting SNVs to be
included in the gene-based-burden association test; Gene, gene name from mtDNA; p, p value from the gene-based burden test; the score test of the weighted
sum of genotypes has the form of statistic, T ¼PjwjUj, where w is a weight for SNVj and Uj is the score statistic for SNVj; Beta and SE are result of regressing the
trait on a weighted sum of genotypes; cMAFUsed, cumulative minor allele frequency; nSNVs, the number of SNVs used in the gene-based burden meta-analysis.with a phenotype. A significant gene-test reflects an aggre-
gate effect of multiple variants in the same area. If most
variants in ND6 are not associated with the phenotype,
the gene-based test might not be significant. Although sta-
tistical significance was not achieved, the association of
MT-ND6 with BMI was suggestive in the burden (p ¼
0.06 [T5] and 0.04 [T1]) and SKAT (p ¼ 0.15 [T5] and
0.08 [T1] tests).
Identification of MT-nDNA Candidate Variants
Associated with Metabolic Traits
We identified 2,282 MT-nDNA candidate genes (see Mate-
rial and Methods) and assessed their association from 20
GWASs with 31 datasets (Table S4). From the MT-nDNA
candidate list, 109 genes reached statistical significance
following correction for multiple testing (Bonferroni p <
1E06) of which 46 were associated with BMI, 2 with
extreme obesity, 26 with WHR, 18 with glucose, 7 with
insulin, 1 with HOMA-B, 1 with HOMA-IR, and 20
with HbA1c, totaling 121 associations (Table 4). The use
of additional SNVs belonging to the same 109 MT-
nDNA genes, but now sourced from the GWAS catalog
for the same 7 traits or any other traits, indicated that
84% (27% improvement) of MT-nDNA genes passed
p % 5E08, while 16% remained at p % 1E06 without
passing the p % 5E08 threshold. Of the MT-nDNA asso-
ciations, GCK (MIM: 138079), MRPL33 (MIM: 610059),
PPARG (MIM: 601487), SLC2A2 (MIM: 138160), AMBRA1
(MIM: 611359), NR1H3 (MIM: 602423), MTCH2 (MIM:
613221), IGF1 (MIM: 147440), and BCL2 (MIM: 151430)
were associated with more than one trait (Figures 2, 3,The AmericS8, and S9). For example, the well-known GCK is a mem-
ber of hexokinases that phosphorylates glucose to
produce glucose-6-phosphate, the first step in most
glucose metabolism pathways, and has pleiotropic effects
(see Discussion).
Enrichment Analysis of MT-nDNA Candidate Genes
The 109 MT-nDNA selected genes are candidates for MT
function based on their protein localization in mitochon-
dria, as well as from mining the published literature (Table
S5). We used Literature Lab and MetaCore software and
the corresponding databases to perform enrichment
analyses, which provided information for MT-nDNA
gene-label relations with terms, pathways, diseases, gene
ontology processes, and clustering (see Supplemental Ma-
terial and Methods, section 8 and Figure S10). When
comparing the 109 MT-nDNA candidate genes versus
the remaining 2,173 (2,282  109), the 109 set showed
enrichment (p ¼ 1.7E12) for ‘‘Signal transduction, Neu-
ropeptide signaling pathways,’’ which included, among
others, POMC (MIM: 176830) and MC4R (MIM: 155541),
while no such enrichment was found for the 2,173 set.
Out of 109 MT-nDNA candidate genes, 21 of the signifi-
cantly associated genes were functionally related with
cholesterol (Table S6 and Figure S11), 13 with glucose
and insulin, and 5 with adipose/obesity. Of the 109
MT-nDNA genes, 13 associated with the ‘‘Type 2 dia-
betes’’54,61,63 term (Table S7) while 18 were associated
with ‘‘Cardiovascular disease’’64–77 (Table S7). (For space
limitation, a detailed enrichment analysis is provided in
the Supplemental Material and Methods, section 8.) Thesean Journal of Human Genetics 104, 112–138, January 3, 2019 119
Table 4. GWAS Findings for Seven Traits (BMI, WHR, Glucose, Insulin, HOMA-B, HOMA-IR, HbA1c) for 109 MT-nDNA Candidate Genes
No SNV Chrom Position Role Gene
Full Gene Name (Cytogenetic
Position) BMI p OBESITY p WHR p GLUC p INS p HOMA-B p HOMAIR p HbA1c p
1 rs622798 1 45549599 upstream-
2 kb
AKR1A1 Aldo-Keto Reductase Family 1
Member A1 (1p34.1)
8.56E07 – – – – – – –
2 rs1280316 1 66843725 Intron WDR78 WD repeat domain 78 (1p31.3) 6.81E07 – – – – – – –
3 rs1093013 1 75634658 Intron SLC44A5 Solute carrier family 44 member 5
(1p31.1)
– – 4.86E17 – – – – –
4 rs6428792 1 119114244 Intron WARS2 Tryptophanyl TRNA Synthetase
2, Mitochondrial (1p12)
– – 7.95E18 – – – – –
5 rs2301453 1 172389027 Intron DNM3 Dynamin 3 (1q24.3) – – 4.38E17 – – – – –
6 rs4844390 1 207761504 Intron CD46 CD46 Molecule, Complement
Regulatory Protein (1q32.2)
– – – – – – – 6.90E07
7 rs11118296 1 219408638 Intron LYPLAL1 Lysophospholipase Like 1 (1q41) – – 3.00E07 – – – – –
8 rs6713865 2 23676937 Intron KLHL29 Kelch like family member 29
(2p24.1)
– – – – – – – 4.39E13
9 rs934778 2 25166355 Intron POMC Proopiomelanocortin (2p23.3) 7.15E07 – – – – – –
10 rs1107238 2 26235376 Intron HADHA Hydroxyacyl-CoA
Dehydrogenase/3-Ketoacyl-CoA
Thiolase/Enoyl-CoA Hydratase
(Trifunctional Protein), Alpha
Subunit (2p23.3)
8.86E07 – – – – – –
11 rs13404446 2 27296386 intron TRIM54 Tripartite Motif Containing 54
(2p23.3)
– – – 3.09E09 – – – –
12 rs4665965 2 27313513 intron MPV17 MPV17, Mitochondrial Inner
Membrane Protein (2p23.3)
– – – 1.83E09 – – – –
13 rs3736594 2 27772914 intron MRPL33 Mitochondrial Ribosomal
Protein L33 (2p23.2)
– – – 3.02E13 4.67E07 – – –
14 rs4346434 2 43992607 intron LRPPRC Leucine Rich Pentatricopeptide
Repeat Containing (2p21)
– – 8.52E08 – – – – –
15 rs16843390 2 209655109 intron MAP2 Microtubule Associated
Protein 2 (2q34)
– – – 3.32E08 – – – –
16 rs715 2 210678331 utr-3-prime CPS1 Carbamoyl-Phosphate Synthase 1
(2q34)
5.81E07 – – – – – – –
17 rs933994 2 218785893 intron CYP27A1 Cytochrome P450 Family 27
Subfamily A Member 1 (2q35)
8.65E07 – – – – – – –
18 rs17036328 3 12348985 intron PPARG Peroxisome Proliferator Activated
Receptor Gamma (3p25.2)
4.27E07 – – – 3.59E12 – – –
(Continued on next page)
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Table 4. Continued
No SNV Chrom Position Role Gene
Full Gene Name (Cytogenetic
Position) BMI p OBESITY p WHR p GLUC p INS p HOMA-B p HOMAIR p HbA1c p
19 rs3729931 3 12585017 intron RAF1 Raf-1 Proto-Oncogene, Serine/
Threonine Kinase (3p25.2)
– – 3.60E10 – – – – –
20 rs11715915 3 49417897 nc-transcript AMT Aminomethyltransferase
(3p21.31)
– – – 4.90E08 – – – –
21 rs12489828 3 52532998 intron NT5DC2 50-Nucleotidase Domain
Containing 2 (3p21.1)
– – 2.60E10 – – – – –
22 rs2365389 3 61250788 intron FHIT Fragile Histidine Triad (3p14.2) 3.75E15 – – – – – – –
23 rs332375 3 66377079 intron SLC25A26 Solute Carrier Family 25 Member
26 (3p14.1)
– – 7.33E07 – – – – –
24 rs1735536 3 128377770 intron EEFSEC Eukaryotic Elongation Factor,
Selenocysteine-TRNA Specific
(3q21.3)
2.95E10 – – – – – – –
25 rs9844666 3 136255374 intron PCCB Propionyl-CoA Carboxylase Beta
Subunit (3q22.3)
7.22E07 – – – – – – –
26 rs11924648 3 171000207 intron SLC2A2 Solute Carrier Family 2 Member 2
(3q26.2)
– – – 1.02E17 – – – 4.05E09
27 rs10012946 4 6291623 intron WFS1 Wolframin ER Transmembrane
Glycoprotein (4p16.1)
– – – 4.17E07 – – – –
28 rs10518406 4 122841742 intron FGF2 Fibroblast Growth Factor 2
(4q28.1)
6.50E07 – – – – – – –
29 rs1458758 4 122914724 intron NUDT6 Nudix Hydrolase 6 (4q28.1) – – 6.22E08 – – – – –
30 rs303084 4 123145793 intron SPATA5 Spermatogenesis associated 5
(4q28.1)
– – 3.40E07 – – – – –
31 rs12654264 5 75352778 intron HMGCR 3-Hydroxy-3-Methylglutaryl-CoA
Reductase (5q13.3)
1.81E08 – – – – – – –
32 rs10478424 5 119453325 intron HSD17B4 Hydroxysteroid 17-Beta
Dehydrogenase 4 (5q23.1)
– – 1.40E07 – – – – –
33 rs2881156 5 135812973 intron SLC25A48 Solute carrier family 25 member
48 (5q31.1)
– 8.10E07 – – – – – –
34 rs3828870 6 16743066 intron ATXN1 Ataxin 1 (6p22.3) – – – – – – – 5.52E07
35 rs1800562 6 26092913 intron HFE Hemochromatosis (6p22.2) – – – – – – – 4.67E28
36 rs1800629 6 31575254 upstream-
2KB
TNF Tumor necrosis factor (6p21.33) – – 7.30E07 – – – – –
37 rs6457796 6 34860776 intron UHRF1BP1 UHRF1 binding protein 1
(6p21.31)
1.15E09 – – – – – – –
(Continued on next page)
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Table 4. Continued
No SNV Chrom Position Role Gene
Full Gene Name (Cytogenetic
Position) BMI p OBESITY p WHR p GLUC p INS p HOMA-B p HOMAIR p HbA1c p
38 rs10434 6 43785475 utr-3-prime VEGFA Vascular endothelial growth
factor A (6p21.1)
– – 8.80E07 – – – – –
39 rs1049354 6 88143732 utr-3-prime CNR1 Cannabinoid receptor 1 (6q15) 9.57E07 – – – – – – –
40 rs9400239 6 108656460 intron FOXO3 Forkhead box O3 (6q21) 1.61E08 – – – – – – –
41 rs1273733 6 121131419 downstream-
500B
TBC1D32 TBC1 domain family member
32 (6q22.31)
3.96E12 – – – – – – –
42 rs1049349 6 121449496 utr-3-prime GJA1 Gap junction protein alpha 1;
synonymous: CX43 (6q22.31)
4.18E15 – – – – – – –
43 rs1293954 6 151669826 intron ESR1 Estrogen receptor 1 (6q25.1-
q25.2)
4.41E09 – – – – – – –
44 rs1203576 7 40808233 intron SUGCT C7orf10 (Succinyl-CoA:Glutarate-
CoA Transferase, 7p14.1)
1.48E10 – – – – – – –
45 rs2908289 7 44184343 intron GCK Glucokinase (7p13) – – – 3.32E88 – 6.00E09 – 2.24E19
46 rs1088867 7 44705214 intron OGDH Oxoglutarate dehydrogenase
(7p13)
7.90E08 – – – – – – –
47 rs16892421 8 106499705 intron OXR1 Oxidation resistance 1 (8q23.1) – – 6.94E07 – – – – –
48 rs7835803 8 120030213 intron DEPTOR DEP domain containing MTOR
interacting protein (8q24.12)
– – – 4.97E07 – – – –
49 rs2777795 9 104910084 intron ABCA1 ATP binding cassette subfamily A
member 1 (9q31.1)
– – 3.13E08 – – – – –
50 rs7023913 9 128255683 downstream-
500B
DNM1 Dynamin 1 (9q34.11) – 7.30E07 – – – – – –
51 rs3829109 9 136362314 intron DNLZ DNL-Type Zinc Finger (9q34.3) – – – 1.13E10 – – – –
52 rs1244497 10 7838019 intron TAF3 TATA-box binding protein
associated factor 3 (10p14)
1.84E11 – – – – – – –
53 rs5030913 10 69246375 intron HKDC1 Hexokinase domain containing 1
(10q22.1)
– – – – – – – 3.56E13
54 rs4745982 10 69330087 intron HK1 Hexokinase 1 (10q22.1) – – – – – – – 2.87E65
55 rs7899106 10 85651147 intron GRID1 Glutamate Ionotropic Receptor
Delta Type Subunit 1 (10q23.2)
2.96E08 – – – – – – –
56 rs7917772 10 102727686 intron SFXN2 Sideroflexin 2 (10q24.32) – – 1.45E09 – – – – –
57 rs1004467 10 102834750 intron CYP17A1 Cytochrome P450 Family 17
Subfamily A Member 1
(10q24.32)
1.18E07 – – – – – – –
(Continued on next page)
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Table 4. Continued
No SNV Chrom Position Role Gene
Full Gene Name (Cytogenetic
Position) BMI p OBESITY p WHR p GLUC p INS p HOMA-B p HOMAIR p HbA1c p
58 rs3740390 10 102878723 intron AS3MT Arsenite Methyltransferase
(10q24.32)
4.82E08 – – – – – – –
59 rs4758633 11 219538 intron SIRT3 Sirtuin 3 (11p15.5) – – – – – – – 3.44E10
60 rs757110 11 17396930 missense ABCC8 ATP Binding Cassette Subfamily
C Member 8 (11p15.1)
4.23E07 – – – – – – –
61 rs10767664 11 27704439 intron BDNF Brain Derived Neurotrophic
Factor (11p14.1)
5.53E13 – – – – – – –
62 rs11038913 11 46538180 intron AMBRA1 Autophagy and beclin 1 regulator
1 (11p11.2)
– – – 4.29E08 4.91E18 – – –
63 rs11039149 11 47255124 intron NR1H3 Nuclear Receptor Subfamily 1
Group H Member 3 (11p11.2)
– – – 1.26E12 4.13E45 – – –
64 rs7118178 11 47637583 intron MTCH2 Mitochondrial carrier 2 (11p11.2) 5.12E08 – – 3.84E14 2.16E29 – – –
65 rs4246215 11 61796827 utr-3-prime FEN1 Flap Structure-Specific
Endonuclease 1 (11p12.2)
– – – 4.46E11 – – – –
66 rs174556 11 61813163 intron FADS1 Fatty acid desaturase 1 (11q12.2) – – – 7.82E18 – – – –
67 rs7943191 11 62561079 intron EEF1G Eukaryotic translation elongation
factor 1 gamma (11q12.3)
– – 4.36E08 – – – – –
68 rs11231150 11 62584330 intron TUT1 Terminal uridylyl transferase 1,
U6 snRNA-specific (11q12.3)
– – 5.20E08 – – – – –
69 rs1017639 11 68831066 intron CPT1A Carnitine Palmitoyltransferase 1A
(11q13.3)
4.96E10 – – – – – – –
70 rs1296252 11 83273268 intron CCDC90B Coiled-Coil Domain Containing
90B (11q13.3)
7.60E08 – – – – – – –
71 rs2110073 12 6966719 intron PHB2 Prohibitin 2 (12p13.31) – – – – – – – 4.44E08
72 rs7311050 12 7013532 intron LPCAT3 Lysophosphatidylcholine
Acyltransferase 3 (12p13.31)
– – – – – – – 8.60E08
73 rs1049380 12 26336611 downstream-
500B
ITPR2 Inositol 1,4,5-Trisphosphate
Receptor Type 2 (12p11.23)
– – 1.42E13 – – – – –
74 rs2408955 12 48105348 upstream-2KB PFKM Phosphofructokinase, muscle
(12q13.11)
– – – – – – – 1.42E15
75 rs35767 12 102481791 missense IGF1 Insulin Like Growth Factor 1
(12q23.2)
– – – – 7.27E08 – 7.57E08 –
76 rs4766578 12 111466567 intron ATXN2 Ataxin 2 (12q24.12) 2.85E07 – – – – – – 1.84E07
77 rs9581856 13 27451478 upstream-2KB MTIF3 Mitochondrial Translational
Initiation Factor 3 (13q12.2)
1.03E08 – – – – – – –
(Continued on next page)
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Table 4. Continued
No SNV Chrom Position Role Gene
Full Gene Name (Cytogenetic
Position) BMI p OBESITY p WHR p GLUC p INS p HOMA-B p HOMAIR p HbA1c p
78 rs1124607 13 27921083 intron PDX1 Pancreatic And Duodenal
Homeobox 1 (13q12.2)
– – – 4.49E07 – – – –
79 rs1325363 13 33192439 intron STARD13 StAR related lipid transfer domain
containing 13 (13q13.1-q13.2)
7.25E08 – – – – – – –
80 rs1078892 13 40563883 intron FOXO1 Forkhead Box O1 (13q14.11) 5.11E08 – – – – – – –
81 rs7143963 14 102838088 intron TRAF3 TNF Receptor Associated Factor 3 2.82E07 – – – – – – –
82 rs12908437 15 98744146 intron IGF1R Insulin Like Growth Factor 1
Receptor
– – – 6.32E07 – – – –
83 rs740862 16 3639677 intron DNASE1 Deoxyribonuclease 1 3.21E07 – – – – – – –
84 rs151181 16 28479196 intron CLN3 CLN3, Battenin 2.10E07 – – – – – – –
85 rs8055138 16 28880144 intron ATP2A1 ATPase Sarcoplasmic/
Endoplasmic Reticulum Ca2þ
Transporting 1
8.17E17 – – – – – – –
86 rs749767 16 31113086 downstream-
500B
BCKDK Branched Chain Ketoacid
Dehydrogenase Kinase
1.21E09 – – – – – – –
87 rs7186084 16 68782357 intron CDH1 Cadherin 1 – – – – – – – 1.09E07
88 rs1847591 16 78908913 intron WWOX WW domain containing
oxidoreductase
– – 9.99E07 – – – – –
89 rs9904685 17 1352101 intron YWHAE Tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase
activation protein epsilon
6.27E07 – – – – – – –
90 rs4646404 17 17516885 intron PEMT Phosphatidylethanolamine N-
Methyltransferase
– – 5.30E11 – – – – –
91 rs9914988 17 28856086 intron ERAL1 Era like 12S mitochondrial rRNA
chaperone 1
– – – – – – – 2.77E11
92 rs242559 17 45948522 intron MAPT Microtubule Associated Protein
Tau
– – – 8.29E07 – – – –
93 rs1319247 17 63106279 intron TANC2 Etratricopeptide repeat, ankyrin
repeat and coiled-coil containing
2
– – 6.02E08 – – – – –
94 rs12940622 17 80641771 intron RPTOR Regulatory Associated Protein Of
MTOR Complex 1
2.49E09 – – – – – – –
95 rs1044661 17 82943144 intron B3GNTL1/
TBCD
UDP-GlcNAc:BetaGal Beta-1,3-N-Acetylglucosaminyltransferase
Like 1/Tubulin Folding CofactorD
– – – – – 1.74E46
96 rs1788785 18 23562376 intron NPC1 NPC Intracellular Cholesterol
Transporter 1
1.98E08 – – – – – – –
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Table 4. Continued
No SNV Chrom Position Role Gene
Full Gene Name (Cytogenetic
Position) BMI p OBESITY p WHR p GLUC p INS p HOMA-B p HOMAIR p HbA1c p
97 rs17066842 18 60373391 upstream-2KB MC4R Melanocortin 4 Receptor 6.40E14 – – – – – – –
98 rs12454712 18 63178651 intron BCL2 BCL2, Apoptosis Regulator – – 1.10E09 – 1.39E07 – – –
99 rs757318 19 18709498 intron CRTC1 CREB Regulated Transcription
Coactivator 1
8.76E09 – – – – – – –
100 rs2075650 19 44892362 intron TOMM40 Translocase Of Outer
Mitochondrial Membrane 40
1.25E08 – – – – – – –
101 rs405509 19 44905579 upstream-2 kb APOE Apolipoprotein E 2.65E07 – – – – – – –
102 rs2281361 20 32140338 intron TM9SF4 ransmembrane 9 superfamily
member 4
9.78E07 – – – – – – –
103 rs878639 20 35306660 intron UQCC1 Ubiquinol-Cytochrome C
Reductase Complex Assembly
Factor 1
– – 1.50E11 – – – – –
104 rs2076574 20 41092733 intron TOP1 DNA topoisomerase I – – 4.11E07 – – – – –
105 rs5750373 22 37028990 intron MPST Mercaptopyruvate
Sulfurtransferase
– – – – – – – 2.17E07
106 rs2284099 22 43155830 intron TSPO Translocator Protein – – 6.65E07 – – – – –
107 rs1050828 23 154536002 missense G6PD Glucose-6-phosphate
dehydrogenase
– – – – – – – 8.23E135
108 rs1448032 23 155052530 intron FUNDC2 FUN14 domain containing 2 – – – – – – – 5.92E17
109 rs5940514 23 155559972 intron TMLHE Trimethyllysine hydroxylase,
epsilon
– – – – – – – 2.22E19
p values in italics annotate SNVs that associate as significant with more than one trait.
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Figure 2. BMI and WHR Association Re-
sults with MT-nDNA Candidate Genesfindings demonstrate the importance of several MT-nDNA
candidates to cardiometabolic outcomes.
eQTLs of MT-nDNA Candidate Variants
Several variants in or near MT-nDNA candidate genes were
identified as expression QTL (eSNV) (Table S8). Based on
RegulomeDB,78 three variants were the best in eSNVs fea-
tures’ ranking. The first was rs242559, intronic to MAPT
(MIM: 157140). Mutations in MAPT associate with lower
mitochondrial nicotinamide adenine dinucleotide
(NADH) levels,79 partially suppress complex I-driven respi-
ration, and lower overall ATP production by oxidative
phosphorylation, with cells relying on glycolysis to main-
tain ATP levels. The second, rs9897919, is a 30 UTR variant
for TBCD (MIM: 604649), tubulin folding cofactor D, and
B3GNTL1 (17q25.3 [MIM: 615337]), a putative glycosyl-
transferase. The third, rs1788821, is intronic to NPC1
(MIM: 607623), which is an intracellular cholesterol trans-
porter with a role in the egress of cholesterol from the en-
dosomal/lysosomal compartments (Table S9).
The findings of RegulomeDB were reinforced by
HaploReg (v.4.1).80 The MT-nDNA variants showed an
enrichment in transcription regulation features. For
instance, rs242559 of MAPT is localized within the pro-
moter histone marks in skeletal muscle, at enhancer his-
tone marks of 16 tissues, and at DNase marks of 4 tissues.
In addition, the rs242559 polymorphism alters the protein
binding site of GATA2, a transcription factor protein that
binds in the promoter regions of target genes (Table S9).
Todetermine the eSNVs’ gene targets in specific tissues,we
used GTEx (v.7.0)81,82 with a summary in Table S8 and
detailed in Table S10. The 42 unique eSNVs were assigned126 The American Journal of Human Genetics 104, 112–138, January 3, 2019to 29 genes targeting regulation of 50
genes, distributed among 13 tissues
(adipose, tibial artery, thyroid, skin,
blood, brain, skeletal muscle, esopha-
geal muscularis, fibroblast, liver,
pancreas, testis, andtibialnerve).There
were 28unique lead and18unique sec-
ondary (LD r2 was < 0.02 to the target
gene’s best eSNV) eSNVs identified
(see Material and Methods). For
example, rs2510344 of NPC1 regulates
C18orf8 in skin and rs11663558 of
NPC1 regulates its own NPC1 gene ex-
pressed highest in subcutaneous adi-
pose tissue (GTEx data).
trans-eQTLs of MT-nDNA Candidate
Variants
We combined the GWAS p value for
the MT-nDNA SNVs with additionalevidence from trans-gene expression regulation for a
specific variant using GWAS3D83 (Figures S12.1–S12.3).
The GWAS3D software selected 16 cell types, which
included chromosomal looping data (5C or ChIA-PET
or Hi-C) and important transcriptional marker data
(H3K4me1, H3K27ac, DHSs, EP300, and CTCF).83
Among several trans-eQTLs, for example, rs2881156
(p ¼ 8.1E07) of SLC25A48 (5q31.1 [MIM: 616150],
Figure S12.1) associated with obesity and trans-regulated
expression of three genes: SAR1B (5q31.1 [MIM:
607690]) involved in protein transport from the endo-
plasmic reticulum to the Golgi (mutations in this gene
are a cause of chylomicron retention disease [MIM:
246700]);84 TRPC7 (5q31.1), a regulator of intracellular
calcium levels;85 and REEP2 (5q31.2 [MIM: 609347]),
which enhances the function of sweet taste receptors86
and is about 80 times higher expressed in brain than
in other tissues (GTEx data).
PPI Network
We analyzed 109MT-nDNA proteins using the PPI network
(see Web Resources)87,88 to identify 4,132 interacting pro-
teins. We present the 15 top genes (Table S11) with highest
PageRank score for PPI,89–91 including the number of PPI, a
short description of gene’s function from Gene Entrez of
NCBI-db, associated trait(s), and association p value(s)
(see also Supplemental Material and Methods, section 9).
From the PPI analysis it is evident that a gene/protein
hub (which is assumed important because of a relatively
large number of interactions) is not necessary, the top-
notch for association with a specific trait, as shown in
the Discussion section.
Figure 3. Glucose and Insulin Association
Results with MT-nDNA Candidate GenesDiscussion
This large, comprehensive study of human mitochondrial
and nuclear mitochondrial genetic variation in relation to
seven key risk factors for metabolic disease provides impor-
tant informationtowardabetterunderstandingof thecauses
and mechanisms of these phenotypes. The use of a two-
tiered approach—i.e., examining mtDNA variants for up to
170,202 individuals and nuclear MT-nDNA candidate
gene polymorphisms for up to339,000 individuals—facil-
itated the evaluation of the genetic underpinnings of seven
metabolic traits reflecting adiposity/obesity and glucose-in-
sulin metabolism and signaling. We identified two mtDNA
SNVs (in MT-ATP6 and the D-loop) associated with WHR
and fasting glucose, a burden of SNVs in a gene (MT-ND3)
associated with BMI, and five rare SNVs of mtDNA (in MT-
ATP6, MT-ND5, and MT-ND6) associated with BMI (2 of 3),
withWHR(2of3), andwith fasting insulin (1of3).Addition-
ally, the MT-nDNA meta-analysis implicated significant as-
sociations with 62 of 109 protein coding candidate genes
(p% 5E08), 29 additional passing the above threshold for
the metabolic traits considered herein or any other traits
querying the GWAS catalog (see Web Resources). Only 16%
of MT-nDNA findings passed p% 1E06 but did not reach
p% 5E08, and thus may be considered as new MT-nDNA
contributions in association with seven metabolic traits
(Tables 4 and S12). Enrichment analysis showed that 13 of
MT-nDNAgeneshavealsobeen identifiedascandidategenes
for T2D risk and 18 for CVD risk. The eQTL analysis of
MT-nDNA candidates revealed that approximately 27% of
associations with seven metabolic traits also act as eSNVs
in regulating expression of other cis-genes. In addition,
trans-eQTL analysis yielded potential support for maternalThe American Journal of Human Geand X chromosome epigenetic gene
expression regulation. ThePPInetwork
analysis identified top PageRank-ed
interacting genes from our significant
MT-nDNA associations, but they did
not necessarily represent the highest
trait-specific associations. Overall,
these findings indicate the important
role of both the nuclear genome and
mtDNA-related variants in energy pro-
duction and, in turn, in the polygenic
architecture of metabolic traits. Below
we summarize and discuss our most
salient study findings.
mtDNA and Metabolic Disease
Associations
To date, nearly 290 genetic causes
for rare disorders of mitochondrialenergy generation have been identified.92 These rare mito-
chondrial genetic diseases commonly result in multiple
clinical phenotypes with varying penetrance, likely due
to differences in heteroplasmy.93 In our study, MT-ATP6
variants MT-8706 and MT-8896 (rs202120082), one with
MAF > 1% and the other one rare, respectively, were
both associated with WHR. MT-ATP6 is part of the pro-
ton-transporting portion of ATP synthase, contributing
to its rotational mechanism.94,95 rs202120082 (MT-8896)
is a missense mutation (p.Ala124Thr) and conversion of
the hydrophobic alanine to an uncharged, polar threonine
at this site may have implications for ATP6’s ability to
effectively pump protons and thus decrease production
of ATP energy units.
MT-16320 (rs62581338; MAF > 1%), in the D-loop,
which contains a few mtDNA replication origins and is
possibly involved in accelerating mtDNA synthesis to
satisfy developmental, physiological, or aging-related de-
mands,96 displayed a significant association with glucose.
MT-16320 is less than 1 kb from a major mtDNA transcrip-
tion initiation site (IT) that overlaps with promoters (in the
D-loop in H-strand, ITH1 at 561 bps and ITH2 at 630, and in
L-strand at 407 bps (ITL1))
97 and is 500 bps downstream of
mitochondrial-encoded cytochrome b (MT-CYB [MIM:
516020], plus strand) and 2 kb upstream of MT-ND6
(minus strand).
Of the five rare SNVs, MT-14272 (rs2853814, missense),
MT-14353, andMT-14584 ofMT-ND6were associated with
adiposity-related traits. MT-ND6 is a core subunit of the
mitochondrial membrane respiratory chain NADH dehy-
drogenase (complex I) and is part of the minimal assembly
required for catalysis. Complex I functions in the transfer
of electrons from NADH into the respiratory chain, whilenetics 104, 112–138, January 3, 2019 127
coupling the flow of electrons to the pumping of protons.
We also demonstrated an association between insulin and
rare variant MT-14124 in the closely relatedMT-ND5 gene.
MT-ND5 is also a core subunit of the mitochondrial mem-
brane respiratory chain NADH dehydrogenase (complex I).
Future studies need to validate these rare variant mtDNA
findings.
It is also important to note that we observed several rare
gene-based suggestive associations between our metabolic
traits (p% 5E02, Tables 2 and 3) and non-protein coding
genes, primarily tRNAs. Mutations within tRNAs that
impact translation would impact all of the mtDNA-en-
coded peptides and consequently would be expected to
have significant effects on oxidative phosphorylation.
TheMT-ND3 gene displayed an aggregate of low-frequency
variants associated with BMI. MT-ND3 is a subunit of the
respiratory chain complex I that is part of the minimal
assembly of core proteins required to catalyze NADH
dehydrogenation and electron transfer to ubiquinone (co-
enzyme Q10). Interestingly, previous studies have demon-
strated increased MT-ND3 gene expression associated with
a higher histological severity of hepatic steatosis.98 Gene-
based meta-analysis burden test, which employed inverse
variance weighting to combine association results from
82 variants in MT-ND3 gene across cohorts, yielded a sig-
nificant association between MT-ND3 and BMI (p ¼
1E03, Figure S17). This figure illustrates that rare alleles
of 82 SNVs contributing in the MT-ND3 meta-analysis
have variable effects.
We used GTEx data for mtDNA genes as assembled by
the Human Protein Atlas team (see Web Resources). They
showed the highest expression of RNA for the MT-ATP6,
MT-ND3, MT-ND5, and MT-ND6 significant mtDNA genes
in the heart and brain, which represent the highest energy-
demanding tissues as compared, for example, to adipose
tissue, in a ratio of about 3:1 (Figure S13). The importance
of MT-nDNA and mtDNA gene polymorphisms in the
heart is supported by recent publications that have
summarized the relation of MT to vascular function,99 as
therapeutic targets in heart failure,100 and specific genes
and pathways that relate to the heart.101,102
MT-nDNA Candidate Genes Associations (Glycemic
Traits)
Glucose sensing in b cells is largely controlled by the hexo-
kinase proteins. Three of the genes encoding hexokinases,
HK1 (MIM: 142600), HKDC1 (MIM: 617221), and GCK,
were part of our MT-nDNA candidate list and were found
to be significantly associated with glucose, HOMA-B,
and/or HbA1c (Table 4). Hexokinases catalyze the conver-
sion of glucose into glucose-6-phosphate. The phosphory-
lation of glucose directly couples extra-mitochondrial
glycolysis to intra-mitochondrial oxidative phosphoryla-
tion. GCK, for example, with pleiotropic effects, produces
an enzyme in the pancreas which plays a role in glucose-
stimulated insulin secretion and affects glucose uptake
and conversion to glycogen in the liver. The GCK128 The American Journal of Human Genetics 104, 112–138, JanuaryGWAS-identified variant rs2908289 (Table 4) has been pre-
viously associated with glucose, HOMA-B, HbA1c,54,60 and
other variants in LD with it, more recently associated with
BMI (rs4607517, r2 ¼ 0.65, p ¼ 8E56),55 with T2D
(rs1799884, r2 ¼ 0.81, p ¼ 5E18),103 and with metabolic
syndrome (rs3757840, r2 ¼ 0.18, p ¼ 4E13).104 Mito-
chondrial metabolism, which drives the respiratory chain
to produce ATP via oxidative phosphorylation, also
contributes to glucose sensing, since disruption of mito-
chondrial oxidative metabolism blocks glucose-stimulated
insulin secretion.40,105–107 Our analysis shows that 13
additional MT-nDNA candidate genes are annotated with
SNVs that associate with glucose/insulin metabolism
(Figure S11). Diabetes mellitus has been associated with
maternally inherited mutations in MT-TK (MIM:
590060), MT-TS2 (MIM: 590085), and MT-TE (MIM:
590025), where the molecular mechanisms involve
impaired translation of mtDNA-encoded proteins.3 In
addition, MT-nDNA candidate genes POLG (15q26.1
[MIM: 174763], DNA polymerase gamma); RRM2B
(8q22.3 [MIM: 604712], a ribonucleotide reductase);
OPA1 (3q29 [MIM: 605290], a nuclear-encoded mitochon-
drial protein with similarity to dynamin-related GTPases);
andMPV17 (2p23.3 [MIM: 137960], a mitochondrial inner
membrane protein) have been associated with diabetes
mellitus, largely due to an impairment in mtDNA mainte-
nance.108 In our study, rs1050828, a missense mutation of
G6PD (Xq28 [MIM: 305900], 154536002 bps; p ¼
8.2E135) was associated with HbA1c. G6PD catalyzes
the rate-limiting step of oxidative pentose-phosphate
pathways, a route for dissimilation of carbohydrates
besides glycolysis. It contributes to the production of
NADPH and pentose phosphatases for fatty acid and
nucleic acid synthesis (Table S6 and Figure S14). G6PD
plays an essential role in maintaining health by protecting
against oxidative damage.109,110 The same rs1050828
variant of G6PD has previously been reported as associated
with HbA1c lowering in African Americans but not in
other populations, leading to misdiagnosis/under-diag-
nosis of T2D.61 In the last century, a number of papers
reported a maternal excess transmission of T2D,111–113
suggesting the possibility of an epigenetic transmission
of diabetes mediated by the mother. To date, two genes,
KLF14 (7q32.2 [MIM: 609393])114 and KCNQ1 (11p15.5-
p15.4 [MIM: 607542]),115,116 have been described as
potential candidates that show parent-of-origin effects in
association with T2D. However, based on our MT-nDNA
list, these two genes are not MT-nDNA candidates. In our
study, GWAS3D analysis identified G6PD as trans-regulated
with the expression of MECP2 (Xq28 [MIM: 300005])
(Figure S12.3).117 MECP2 binds to methylated DNA and
mediates transcriptional repression through interaction
with histone deacetylase and the corepressor SIN3A
(15q24.2 [MIM: 607776]) (Figure S14). Lai et al.118 reported
meta-results that T2D-affected case subjects with G6PD
deficiency had two times higher odds of developing
diabetes than unaffected control subjects.119 Furthermore,3, 2019
G6PD protein has a weak score of 1 out of 5 to be found in
MT. G6PD is mainly localized in the cytosol and also to the
microtubule-organizing center and vesicles (Human Pro-
tein Atlas). G6PD protein has 69 interactions and was
ranked 65th by the PageRank algorithm for the importance
of PPI. These results taken together may suggest that G6PD
contributes to the maternal epigenetics of T2D, through X
chromosome inheritance and less through MT. Other
candidates of MT-nDNA genes that may contribute to
mitochondrial epigenetics120 are DNMT1 (19p13.2 [MIM:
126375], DNA methyltransferase 1), POLRMT (19p13.3
[MIM: 601778], RNA polymerase mitochondrial), TFB1M
(6q25.3 [MIM: 607033], transcription factor B1, mitochon-
drial), TFB2M (1q44 [MIM: 607055], transcription factor
B2, mitochondrial), and TFAM (10q21.1 [MIM: 600438],
transcription factor A, mitochondrial), but showed no sig-
nificant associations with existing data for the traits stud-
ied (for BMI: rs6926853, TFB1M, p ¼ 1.3E03;45 WHR:
rs10465617, TFB2M, p ¼ 3.1E03;43 glucose: rs4804124,
DNMT1, p ¼ 7.3E05;54 insulin: rs7253062, DNMT1, p ¼
4.4E03;55 HOMA-B: rs12462004, DNMT1, p ¼
4.4E03;54 HOMA-IR: rs892189, DNMT1, p ¼ 7E04;54
HbA1c: rs11006132, TFAM, p ¼ 2.4E0361).
MT-nDNA Candidate Genes Associations (Adipose
Traits)
We found that a total of 26 of the 109 MT-nDNA candidate
genes showed significant associations with WHR (Tables 4
and S6 and Figure S11). For example, WARS2 (1p12 [MIM:
604733]) encodes the MT tryptophanyl-tRNA synthase.
We observed an intronic rs6428792 of WARS2 in associa-
tion with WHR (p ¼ 7.95E18).50 Another SNV,
rs10923724 in LD with rs6428792, r2 ¼ 0.29, WHR p ¼
9E25)52 upstream of WARS2 but closer to downstream
of TBX15 (1p12 [MIM: 604127]), modifies WARS2 expres-
sion in skeletal muscle (p ¼ 1.1E-36) and in adipose-subcu-
taneous tissues (p ¼ 1Es29) (GTEx data). In our PPI
analysis of 109 MT-nDNA genes and 4,132 interactants,
WARS2 showed two interactions and was ranked 2,028th
based on the PageRank algorithm. Taken together, these
findings (our study, GTEx, and GWAS) suggest that associ-
ations with WHR might be mediated also by differential
expression of WARS2.121
There were 48 MT-nDNA candidates associating with
BMI. For example, NPC1 (18q11.2, Tables 4 and S6) has
been associated with early childhood onset and adult
morbid obesity.122NPC1 (a cholesterol transporter) is high-
ly expressed in human white adipose tissue adipocytes
with increased levels in obese individuals.123 Our lead
SNV rs1788785 is an eSNV for NPC1 and is not in LD
with the best NPC1 eSNV, supporting NPC1 as a candidate
gene for obesity. Indeed, studies in mice have shown that a
non-functioning NPC1 resulted in late-onset weight loss
and less food intake.124 In humans, NPC1 is part of the
cholesterol metabolism pathway (see Web Resources).
Recently, NPC1 mutant cells were reported to have
fragmented mitochondrial networks, increased respira-The Americtion, alterations in the composition of the respiratory
chain complex, and a substantial reduction in the cellular
ATP level. Thus, a primary lysosomal defect in NPC1
mutant fibroblasts is accompanied by deregulation of the
organization and function of the mitochondrial
network.125 NPC1 was ranked 241st and had 13 interac-
tions in the PPI network.
Other notable obesity-related variants/genes among
MT-nDNA candidates include POMC (2p23.3, adrenocorti-
cotropic peptide/hormone, p ¼ 7.2E07), which binds to
melanocortin 2 receptor (MC2R, 18p11.21 [MIM:
607397]), stimulating release of cortisol, a steroid stress-
response hormone. MC4R (18q21.32, p ¼ 6.4E14) was
ranked the 3rd in BMI-effects compared to FTO (16q12.2
[MIM: 610966]), the top ranked for BMI effects in Speliotes
et al.,41 Locke et al.,46 andWinkler et al.48MC4R is another
member of the melanocortin receptor family, which has a
central role in energy homeostasis and somatic growth.
MC4R is ranked the 82nd, with 12 PPI, when analyzed
for the importance of PPI using the PageRank algorithm.
CNR1 (6q15 [MIM: 114610], cannabinoid receptor, p ¼
9.6E07) influences mitochondrial respiration. CRTC1
(19p13.11 [MIM: 607536], CREB regulated transcription
coactivator 1, p ¼ 8.8E09) is a potent coactivator of
PGC1a (4p15.2, officially known as PPARGC1A [MIM:
604517]), a transcriptional coactivator that regulates the
genes involved in energy metabolism, and inducer of
mitochondrial biogenesis.
MTCH2 (11p11.2, mitochondrial carrier homolog 2,
rs7118178, BMI p ¼ 5.1E08) was 9th in BMI effects
compared to FTO in Speliotes et al.41 and 16th in Locke
et al.46 MTCH2 is located in the inner membrane of MT,
highly expressed in white adipose tissue and adipocytes,
and is thought to play a regulatory role in adipocyte differ-
entiation and biology.126 The MTCH2 GWAS-variant
rs7118178 (Table 4) has been associated with BMI,46
glucose,36,55 and pro-insulin58 (Figure 4, T1-4). MTCH2
has 87 protein interactions and ranked 14th when
analyzed for the importance of PPI using PageRank algo-
rithm. MTCH2 deficiency in mouse muscle has been
shown to be beneficial, protecting mice from the obeso-
genic effect of high-fat diets, most likely the result of an
increase in mitochondrial metabolism. MTCH2 is pro-
posed as a repressor of muscle mitochondrial metabolism
and size.127 Using both GWAS and eQTL information,
three MTCH2 SNVs co-localize within a 15 kbp DNA re-
gion. Based on GTEx data, rs4752856 in MTCH2 (Figure 4,
T6) regulates gene expression of C1QTNF4 (11p11.2 [MIM:
614911]) and PSMC3 (11p11.2 [MIM: 186852]) in subcu-
taneous adipose tissue. rs3817335, which is in high LD
(r2 ¼ 0.903) with rs4752856, regulates SLC39A13
(11p11.2 [MIM: 608735]) in tibial artery tissue, while
rs7118178 (in less LD to two other SNVs, r2 ¼ 0.083) regu-
lates CELF1 (11p11.2 [MIM: 601074]) in tibial nerve tissue,
and with results similar to the best eSNVs for the
mentioned genes and in high LD with their eSNVs
(Figure 4, T5). C1QTNF4 is reported as a potential cytokinean Journal of Human Genetics 104, 112–138, January 3, 2019 129
Figure 4. Selected SNVs ofMTCH2 Significantly Associating with BMI, Glucose, Insulin, and a Few of Them Regulating the Expression
(eSNVs) of at Least Four Genes: C1QTNF4, SLC39A13, PSMC3, and CELF1
First, we used LocusZoom142 for plotting regional information for MTCH2 selected SNVs, which have been reported by large GWAS
publications (for BMI41 [T1], for glucose55 [T2], for proinsulin58 [T3], and another large analysis for glucose56 [T4]), for strength and
extent of the association signal relative to genomic position, local linkage disequilibrium, and recombination patterns and the positions
of genes in the region. Second, we usedGTEx81 data to identify the SNVs ofMTCH2 that are eSNVs by influencing the expression of other
cis-target-genes (C1QTNF4, PSMC3, SLC39A13, CELF1) (T6). Third, we verified whether these eSNVs of MTCH2 (connected with blue
dashed lines) are true expression regulators, by identifying the best eSNVs of the four target genes (T5, regulation effects shown with
orange-dashed lines) and evaluating the LD r2 between the MTCH2 eSNV, e.g., rs4752856 (T6) and the best eSNV rs10838724 (T5) for
the corresponding target gene (C1QTNF4), which was found to be 0.829 in adipose-subcutaneous tissue (T6). Fourth, the MTCH2
SNVs serving as eSNVs for the four cis-target-genes, shown in T6, colocalize in about 15K bps region. Thus, MTCH2 associates with
BMI, glucose, and proinsulin, and among others influence the gene expression of other cis-genes (C1QTNF4, PSMC3, SLC39A13,
CELF1), who in itself contribute also to individuals’ obesity risk (see Discussion).that can induce the activation of both NFKB1 (MIM:
164011) and IL6/STAT3 (MIM: 147620/102582) signaling
pathways128 and acts in the hypothalamus to modulate
food intake and peripheral energy expenditure.129 PSMC3
is involved in ATP-dependent degradation of misfolded
and damaged proteins and in removal of no longer
required proteins. This protein is also involved in cell cycle
progression, apoptosis, and DNA damage repair. A knock-
down of PSMC3 in human immortalized fibroblasts
increased cell proliferation.130 CELF1 has been associated
with Alzheimer disease and obesity.131 Consequently,
MTCH2 SNVs regulate gene expression of other cis-genes
related to obesity, food intake, and/or cell number. Thus,
MTCH2 effects on BMI may be more complex than previ-
ously accounted for.
Other Functions of MT-nDNA Candidate Genes
Mitochondrial inheritance has been previously associated
with obesity, metabolic syndrome, insulin resistance,
type 2 diabetes, and cardiovascular disease.3,40,132–135
The complex genetics of MT affects processes of glucose,
lipid, and amino acid catabolism, with ATP as the final
energy product. By-products of these processes play an
important role in signaling (e.g., ROS) and are used for130 The American Journal of Human Genetics 104, 112–138, Januaryepigenetic modifications (e.g., acetyl CoA). In our study,
we would expect a preponderance of glycemic and lipid
genes and proteins. Out of 109 MT-nDNA candidate
genes, 21 of the significantly associated genes were
functionally related with cholesterol (Table S6 and
Figure S11), 16 with glucose and insulin, and 5 with ad-
ipose/obesity. The 109 MT-nDNA candidate genes have
other functions too. For example, rs1044661 is located
at 17q25.3, overlapping two genes that run in opposite
strands: TBCD (involved in tubulin folding as cofactor
D) and B3GNTL1 (a putative glucosyltransferase). This
SNV was associated with HbA1c (p ¼ 1.74E46).61
Recently, Francis et al.136 hypothesized that the interac-
tion between TBCD (17q25.3) and ARL2 (11q13.1
[MIM: 601175]) suggest that ARL2 serves as regulator of
both mitochondrial fusion and microtubule dynamics.
In 109 MT-nDNA candidates, WDR78 (1p31.3), TRIM54
(2p23.3 [MIM: 606474], regulating titin kinase [control-
ling elasticity in muscle] and microtubule-dependent
signaling pathways in striated muscles), DNM3 (1q24.3
[MIM: 611445], involved in vesicular transport and
with biased expression in brain), MAP2 (2q34 [MIM:
157130], involved in microtubule assembly and neuro-
genesis), GJA1 (6q22.31 [MIM: 121014], involved in the3, 2019
contraction of heart) and MAPT (17q21.31, expressed in
nervous system) produce microtubule-associated proteins
in interaction with MT (Table S6 and Figure S11). It
should be noted that rs1050828, a missense mutation
of G6PD residing on X chromosome, may impact
HbA1c through non-glycemic factors rather than glucose
metabolism.61 Additional functions of MT-nDNA candi-
date genes are described in the Supplemental Material
and Methods, section 7.
Strengths and Limitations
Our study had many strengths. We used large sample sizes
for studying mtDNA and MT-nDNA. At the mtDNA level
we validated SNVs used per cohort and imputed based on
Cosmopolitan MT-1000 Genomes. At the MT-nDNA level
we used the strength of many consortia contributions for
associations with seven traits. As a consequence, we per-
formed comprehensive mtDNA and MT-nDNA analyses.
The sevenmtDNA variants significant associations showed
no statistical significant deviations from the homogeneity/
similarity of beta contributions before meta-pooling across
studies as reported with Het-p in Table 1, as well as graph-
ically represented in the Forest plot (Figure S16). For sup-
porting MT-future studies, we have provided mtDNA up-
dated Tables S15–S28 for arrays used in this study
including MitoMap annotation. Also, we include Table
S32 of predictions from the bioinformatics platforms that
have been shown to have the highest sensitivity and spec-
ificity for the mtDNA variants.137 Our study also had some
limitations. Rare mtDNAmutations are usually heteroplas-
mic point mutations and/or mtDNA lesions that typically
result in a primary mitochondrial disease, which can man-
ifest as a broad range of clinical outcomes. In this study we
have interrogated the effect of inherited mtDNA variants,
much commoner in the population than typical mtDNA
mutations. Therefore, while there is a great deal of litera-
ture linking inherited mtDNA variants to disease, many
of these studies have limited statistical power138 and
several have never been independently replicated. So in
many respects there is not a great deal of robust literature
to call upon. The harmonization of mtDNA in each study
was dependent on the number of mtDNA variants and
their quality. Some variants were dropped before perform-
ing any imputation, because low-quality variants matched
not only to the mtDNA genome, but also to nuclear
genome (see mtDNA Variant Harmonization in Material
and Methods). A number of quality-control filters were
applied to mtDNA, which reduced individual sample size
per marker or the number of useful markers. We did not
address the association of significant markers by gender,
because in our study sample sizes per mtDNA marker
were variable and often small.
Perspective and Conclusion
We focused on associations of MT with adipose and gly-
cemic traits, yet we acknowledge that there is still much
to be learned from other traits, for example for triglycer-The Americides, high-density lipoprotein cholesterol, and C-reactive
protein.46,139–141 Notably, we identified 21 MT genes of
lipid metabolism, although this was not the direct focus
of our study. For example, TMLHE (Xq28 [MIM: 300777],
trimethyllysine dioxygenase associated with HbA1c, p ¼
2.2E19) is the first enzyme in the carnitine biosynthesis
pathway. Carnitine play an essential role in the transport
of activated fatty acids across the inner mitochondrial
membrane and this gene is ubiquitous for its expression
in heart. Hence, MT associations with other traits at the
consortia-level remain to be explored. In conclusion,
we identified common, rare SNVs, and a gene burden
of genetic mtDNA variants, as well as 109 MT-nDNA
genes associated with metabolic traits. Of the 109 MT-
nDNA candidate genes, a subset pointed to associations
with adipose, glucose metabolism, T2D, and CVD, and
a subset of SNVs was inferred to contribute for differen-
tial regulatory genes expression. We documented in this
study that the MT-candidates (SNVs/genes) have special
contributions for functioning and energy homeostasis
in adipose tissues and to glucose metabolism and insulin
signaling.Accession Numbers
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